Sunday 18 October 2026
Export RNA’s income statement to Excel — free account
Atrium Therapeutics, Inc.
RNA
Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024. Revenue growth for three consecutive years.
7.67
0.15
−1.92%
Follow RNA
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| (40.74%) | — | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(23.08%) | 0.00% | 0.00% | — | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(3.40) | 0.00 | — | 0.00 | |
Free Cash Flow |
(58.08) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(12.13%) | 0.00% | 0.00% | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
186.14% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
128.45% | — | — | — | |
Share Based Compensation of Revenue |
57.08% | — | — | — | |
Operating CF/Net income |
1.02 | — | — | — | |
Depreciation/Fixed assets |
0.09 | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | — | — | — | |
Revenue per Share |
1.64 | 0.00 | — | 0.00 | |
Operating CF per Share |
(3.40) | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates